These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

579 related items for PubMed ID: 27485081

  • 1. Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases.
    Pers YM, Jorgensen C.
    Immunotherapy; 2016 Sep; 8(9):1091-6. PubMed ID: 27485081
    [Abstract] [Full Text] [Related]

  • 2. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
    Robak T, Robak E.
    BioDrugs; 2011 Feb 01; 25(1):13-25. PubMed ID: 21090841
    [Abstract] [Full Text] [Related]

  • 3. Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?
    Reddy V, Dahal LN, Cragg MS, Leandro M.
    Drug Discov Today; 2016 Aug 01; 21(8):1330-8. PubMed ID: 27343722
    [Abstract] [Full Text] [Related]

  • 4. Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis.
    Dörner T, Isenberg D, Jayne D, Wiendl H, Zillikens D, Burmester G, International Roundtable on B cells as Therapeutic Target for Intervention.
    Autoimmun Rev; 2009 Dec 01; 9(2):82-9. PubMed ID: 19716441
    [Abstract] [Full Text] [Related]

  • 5. [B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].
    Tanaka Y.
    Yakugaku Zasshi; 2009 Jun 01; 129(6):675-9. PubMed ID: 19483410
    [Abstract] [Full Text] [Related]

  • 6. [Research progress on B cell surface molecules targeted therapy in rheumatoid arthritis].
    Di W, Chang Y, Wu YJ, Wei W.
    Sheng Li Ke Xue Jin Zhan; 2011 Jun 01; 42(3):175-80. PubMed ID: 21932514
    [Abstract] [Full Text] [Related]

  • 7. Long term treatment of rheumatoid arthritis with rituximab.
    Caporali R, Caprioli M, Bobbio-Pallavicini F, Bugatti S, Montecucco C.
    Autoimmun Rev; 2009 Jun 01; 8(7):591-4. PubMed ID: 19393205
    [Abstract] [Full Text] [Related]

  • 8. Ocrelizumab: a step forward in the evolution of B-cell therapy.
    Kausar F, Mustafa K, Sweis G, Sawaqed R, Alawneh K, Salloum R, Badaracco M, Niewold TB, Sweiss NJ.
    Expert Opin Biol Ther; 2009 Jul 01; 9(7):889-95. PubMed ID: 19463076
    [Abstract] [Full Text] [Related]

  • 9. B cell-directed therapy in rheumatoid arthritis--clinical experience.
    Panayi GS.
    J Rheumatol Suppl; 2005 Feb 01; 73():19-24; discussion 29-30. PubMed ID: 15693112
    [Abstract] [Full Text] [Related]

  • 10. B lymphocyte depletion in rheumatoid arthritis: targeting of CD20.
    Edwards JC, Leandro MJ, Cambridge G.
    Curr Dir Autoimmun; 2005 Feb 01; 8():175-92. PubMed ID: 15564721
    [Abstract] [Full Text] [Related]

  • 11. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases.
    Baker D, Roberts CAK, Pryce G, Kang AS, Marta M, Reyes S, Schmierer K, Giovannoni G, Amor S.
    Clin Exp Immunol; 2020 Nov 01; 202(2):149-161. PubMed ID: 32671831
    [Abstract] [Full Text] [Related]

  • 12. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.
    Tanaka Y.
    Intern Med; 2007 Nov 01; 46(16):1313-5. PubMed ID: 17704614
    [No Abstract] [Full Text] [Related]

  • 13. [Targeting CD20 in rheumatoid arthritis].
    Saito K, Tanaka Y.
    Nihon Rinsho; 2007 Jul 01; 65(7):1243-9. PubMed ID: 17642239
    [Abstract] [Full Text] [Related]

  • 14. B cell-directed therapies in multiple sclerosis.
    Gasperi C, Stüve O, Hemmer B.
    Neurodegener Dis Manag; 2016 Jul 01; 6(1):37-47. PubMed ID: 26782316
    [Abstract] [Full Text] [Related]

  • 15. Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders.
    Castillo J, Milani C, Mendez-Allwood D.
    Expert Opin Investig Drugs; 2009 Apr 01; 18(4):491-500. PubMed ID: 19335277
    [Abstract] [Full Text] [Related]

  • 16. Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises.
    Bagacean C, Zdrenghea M, Tempescul A, Cristea V, Renaudineau Y.
    Immunotherapy; 2016 May 01; 8(5):569-81. PubMed ID: 27140410
    [Abstract] [Full Text] [Related]

  • 17. B cell depletion in the treatment of multiple sclerosis.
    Myhr KM, Torkildsen Ø, Lossius A, Bø L, Holmøy T.
    Expert Opin Biol Ther; 2019 Mar 01; 19(3):261-271. PubMed ID: 30632834
    [Abstract] [Full Text] [Related]

  • 18. B-cell: a logical target for treatment of rheumatoid arthritis.
    Youinou P, Jamin C, Saraux A.
    Clin Exp Rheumatol; 2007 Mar 01; 25(2):318-28. PubMed ID: 17543163
    [Abstract] [Full Text] [Related]

  • 19. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis.
    Looney RJ.
    Rheumatology (Oxford); 2005 May 01; 44 Suppl 2():ii13-ii17. PubMed ID: 15851522
    [Abstract] [Full Text] [Related]

  • 20. [B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases].
    Kondo S, Akashi T, Katsuta H, Iwakiri R, Anzai K, Nagafuchi S, Niho Y, Harada M.
    Fukuoka Igaku Zasshi; 2005 Apr 01; 96(4):86-92. PubMed ID: 15991605
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.